Zantac FDA Recall for Probable Cancer-Causing Contaminant– Class Action Investigation Into Drugmakers Sanofi and GlaxoSmithKline

Chimicles Schwartz Kriner & Donaldson-Smith LLP (CSK&D) is investigating the April 1, 2020 Food and Drug Administration (FDA) recall of prescription and over-the-counter (OTC) rantidine drugs, known by the brand name Zantac.

GlaxoSmithKline (GSK), producer of prescription Zantac, issued a recall on October 8, 2019, days after the FDA found “unacceptable” levels of a probable cancer-causing contaminant in the drug.  OTC Zantac is sold by drugmaker Sanofi, which voluntarily recalled its over-the-counter version on October 18, 2019, “due to inconsistencies in preliminary test results” for possible contaminants.  The April 1 FDA recall was prompted by its ongoing investigation into contaminants which, over time and when stored at higher-than-normal temperatures, pose a risk to public health as a human carcinogen.  The FDA is sending letters to all manufacturers of ratidine requesting that they withdraw products from the market, and is advising consumers to stop taking any tablets or liquid medications they currently have.

Accordingly, both GlaxoSmithKline and Sanofi were allegedly labelling, marketing and selling Zantac with false and/or deceptive statements, and thereby misrepresented the risk of using Zantac.

If you bought Zantac, either with a prescription or over-the-counter, please contact the attorney(s) listed below.

(*) Indicates required field: When communicating with us through this site or otherwise in connection with a matter for which we do not already represent you, your communication may not be treated as privileged or confidential, and does not create an attorney-client relationship between you and our Firm.

Attorneys for this case:

Benjamin F. Johns
Beena M. McDonald